AI Dog Vaccine: Complete Technical Plan Revealed with 300GB Genetic Data and Chatbot Collaboration

According to monitoring by 1M AI News, Paul Conyngham, founder of an Australian AI consulting company, published a lengthy post on X, revealing for the first time his complete technical plan for designing a personalized mRNA cancer vaccine for his dog Rosie using AI chatbots. Rosie, an 8-year-old Staffordshire Bull Terrier mix, was diagnosed with malignant mast cell cancer in May 2024, with veterinarians estimating only a few months left to live. Conyngham, who lacks a biological background, relied on the collaboration of three AI chatbots: ChatGPT, Gemini, and Grok throughout the process. He first completed Rosie’s whole genome sequencing and RNA sequencing, totaling approximately 300GB of raw data, with the help of Professor Martin Smith from the Ramaciotti Centre at the University of New South Wales (UNSW) and the Garvan Institute team. He then used ChatGPT to design the bioinformatics analysis workflow, modeling the mutated protein structure with AlphaFold 2, ultimately identifying the c-KIT gene mutation through cross-validation of DNA and RNA data and screening seven new antigen targets. Gemini Pro 2 was responsible for constructing the multi-epitope vaccine sequence, while Grok 3 completed the structural stability validation. The vaccine was manufactured by Professor Pall Thordarson’s team at the UNSW mRNA Research Institute and administered by Professor Rachel Allavena’s team at the University of Queensland’s veterinary school. The treatment plan is not limited to the vaccine but is a tri-therapy designed with the help of AI: the mRNA vaccine trains the immune system to recognize cancer cells, tyrosine kinase inhibitors block the proliferation and angiogenesis of c-KIT mutation-driven cancer cells, and PD-1 checkpoint inhibitors relieve the suppression signals from cancer cells to T cells. The administration sequence of the three treatments was planned with the assistance of ChatGPT and Gemini, as immunosuppressive drugs and immune-activating vaccines cannot be used simultaneously. Treatment began in December 2025, and three months later, tumors in two locations on Rosie’s legs significantly shrank, but a tumor on her hip did not respond and was surgically removed for genomic analysis, which preliminarily showed that its mutation characteristics differed from the cancer targeted by the vaccine design. Conyngham summarized that AI chatbots enabled him to ‘possess the capabilities of a research institute alone,’ covering process planning, educational learning, technical troubleshooting, compliance documentation, and scientific design. He stated that he is evaluating the possibility of scaling this process, emphasizing that ‘it won’t stop at just one dog.’ Experts caution that this is merely a single case and not a controlled study, and it does not constitute evidence that AI can cure cancer.